Praveen Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Praveen Sharma has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Ravindra Kumar Garg
Department of Neurology, Era’s Lucknow Medical College & Hospital, Lucknow, India
12 shared publications - Imran Rizvi
King George’s Medical University, Lucknow, India
10 shared publications - Ravi Uniyal
Department of Neurology, King George’s Medical University, Lucknow, India
10 shared publications - Neeraj Kumar
Department of Neurology, King George’s Medical University, Lucknow, India
8 shared publications - Shweta Pandey
Department of Neurology, King George’s Medical University, Lucknow, India
8 shared publications - Hardeep Singh Malhotra
King George's Medical University, Lucknow, UP, 226003, India
7 shared publications
Latest Publications
- 3 October 2026
- Published by Wiley in Diagnostic Cytopathology
Fine‐Needle Aspiration Cytology of Gingival Acute Promyelocytic Leukemia: Cytomorphologic Clues to an Unusual Extramedullary Presentation
Introduction: Acute promyelocytic leukemia (APL) is a hematologic emergency in which prompt diagnosis is essential to reduce early hemorrhagic mortality. Although oral manifestations are well recognized in acute myeloid leukemia, gingival infiltration is distinctly uncommon in APL, and concomitant central nervous system (CNS) involvement at presentation is exceptionally rare. As gingival lesions may be sampled during their diagnostic evaluation, recognition of characteristic cytomorphology on fine‐needle aspiration cytology (FNAC) can provide an early clue to the underlying hematologic malignancy. Case: A 30‐year‐old man presented with excessive post‐tooth‐extraction bleeding, diffuse gingival enlargement, and left facial palsy. FNAC of the gingival swelling demonstrated scattered abnormal hypergranular promyelocytes with folded nuclei, multiple Auer rods, and occasional faggot cells in a hemorrhagic background, strongly suggestive of APL. Subsequent peripheral blood flow cytometry, bone marrow examination, and molecular testing confirmed PML::RARA ‐positive APL. Cerebrospinal fluid cytology and flow cytometry established concurrent CNS involvement. Treatment with all‐trans retinoic acid and arsenic trioxide resulted in hematologic remission and complete resolution of the gingival enlargement. Conclusions: This case highlights the diagnostic value of gingival FNAC in the rapid identification of uncommon extramedullary presentations of APL. Knowledge of the characteristic cytomorphologic features facilitates early diagnosis and timely initiation of the life‐saving differentiation therapy.
- 3 October 2026
- Published by Wiley in Diagnostic Cytopathology
Fine‐Needle Aspiration Cytology of Gingival Acute Promyelocytic Leukemia: Cytomorphologic Clues to an Unusual Extramedullary Presentation
Introduction: Acute promyelocytic leukemia (APL) is a hematologic emergency in which prompt diagnosis is essential to reduce early hemorrhagic mortality. Although oral manifestations are well recognized in acute myeloid leukemia, gingival infiltration is distinctly uncommon in APL, and concomitant central nervous system (CNS) involvement at presentation is exceptionally rare. As gingival lesions may be sampled during their diagnostic evaluation, recognition of characteristic cytomorphology on fine‐needle aspiration cytology (FNAC) can provide an early clue to the underlying hematologic malignancy. Case: A 30‐year‐old man presented with excessive post‐tooth‐extraction bleeding, diffuse gingival enlargement, and left facial palsy. FNAC of the gingival swelling demonstrated scattered abnormal hypergranular promyelocytes with folded nuclei, multiple Auer rods, and occasional faggot cells in a hemorrhagic background, strongly suggestive of APL. Subsequent peripheral blood flow cytometry, bone marrow examination, and molecular testing confirmed PML::RARA ‐positive APL. Cerebrospinal fluid cytology and flow cytometry established concurrent CNS involvement. Treatment with all‐trans retinoic acid and arsenic trioxide resulted in hematologic remission and complete resolution of the gingival enlargement. Conclusions: This case highlights the diagnostic value of gingival FNAC in the rapid identification of uncommon extramedullary presentations of APL. Knowledge of the characteristic cytomorphologic features facilitates early diagnosis and timely initiation of the life‐saving differentiation therapy.
- Open Access
- 16 May 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 21
VEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort
Background: VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the UBA1 gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome. Materials and methods: A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization. Results: A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T>C Exon 3) (55%), p.Met41Val (c.121 A>G Exon 3) (27%), p.Met41Leu (c.121 A>C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G>C) (9%). p.Met41Val is associated with inferior overall survival (OS). Conclusion: This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.
- 16 May 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 21
Open AccessVEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort
Background: VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the UBA1 gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome. Materials and methods: A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization. Results: A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T>C Exon 3) (55%), p.Met41Val (c.121 A>G Exon 3) (27%), p.Met41Leu (c.121 A>C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G>C) (9%). p.Met41Val is associated with inferior overall survival (OS). Conclusion: This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.
- 17 March 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 146, 108288
Predictors of response to botulinum toxin treatment in patients with primary hemifacial spasm: A prospective cohort study
- 17 March 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 146, 108288
Predictors of response to botulinum toxin treatment in patients with primary hemifacial spasm: A prospective cohort study
- 11 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-2
ZBTB16::RARA Translocated Acute Promyelocytic Leukemia with Erythrophagocytosis and Rod-Like Crystalline Inclusions
- 11 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-2
ZBTB16::RARA Translocated Acute Promyelocytic Leukemia with Erythrophagocytosis and Rod-Like Crystalline Inclusions
- Open Access
BoMBR: An Annotated Bone Marrow Biopsy Dataset for Segmentation of Reticulin Fibers
Bone marrow reticulin fibrosis is associated with varied benign as well as malignant hematological conditions. The assessment of reticulin fibrosis is important in the diagnosis, prognostication and management of such disorders. The current methods for quantification of reticulin fibrosis are inefficient and prone to errors. Therefore, there is a need for automated tools for accurate and consistent quantification of reticulin. However, the lack of standardized datasets has hindered the development of such tools. In this study, we present a comprehensive dataset that comprises of 201 Bo ne M arrow B iopsy images for R eticulin (BoMBR) quantification. These images were meticulously annotated for semantic segmentation, with the focus on performing reticulin fiber quantification. This annotation was done by two trained hematopathologists who were aided by Deep Learning (DL) models and image processing techniques that generated a rough automated annotation for them to start with. This ensured precise delineation of the reticulin fibers alongside other cellular components such as bony trabeculae, fat, and cells. This is the first publicly available dataset in this domain with the aim to catalyze advancements the development of computational models for improved reticulin quantification. Further, we show that our annotated dataset can be used to train a DL model for a multi-class semantic segmentation task for robust reticulin fiber detection task (Mean Dice score: 0.92). We use these model outputs for the Marrow Fibrosis (MF) grade detection and obtained a Mean Weighted Average F1 score of 0.656 with our trained model. Our code for preprocessing the dataset is available at https://github.com/AI-in-Medicine-IIT-Ropar/BoMBR_dataset_preprocessing .
Open AccessBoMBR: An Annotated Bone Marrow Biopsy Dataset for Segmentation of Reticulin Fibers
Bone marrow reticulin fibrosis is associated with varied benign as well as malignant hematological conditions. The assessment of reticulin fibrosis is important in the diagnosis, prognostication and management of such disorders. The current methods for quantification of reticulin fibrosis are inefficient and prone to errors. Therefore, there is a need for automated tools for accurate and consistent quantification of reticulin. However, the lack of standardized datasets has hindered the development of such tools. In this study, we present a comprehensive dataset that comprises of 201 Bo ne M arrow B iopsy images for R eticulin (BoMBR) quantification. These images were meticulously annotated for semantic segmentation, with the focus on performing reticulin fiber quantification. This annotation was done by two trained hematopathologists who were aided by Deep Learning (DL) models and image processing techniques that generated a rough automated annotation for them to start with. This ensured precise delineation of the reticulin fibers alongside other cellular components such as bony trabeculae, fat, and cells. This is the first publicly available dataset in this domain with the aim to catalyze advancements the development of computational models for improved reticulin quantification. Further, we show that our annotated dataset can be used to train a DL model for a multi-class semantic segmentation task for robust reticulin fiber detection task (Mean Dice score: 0.92). We use these model outputs for the Marrow Fibrosis (MF) grade detection and obtained a Mean Weighted Average F1 score of 0.656 with our trained model. Our code for preprocessing the dataset is available at https://github.com/AI-in-Medicine-IIT-Ropar/BoMBR_dataset_preprocessing .
- Open Access
- 5 July 2024
- Published by Wolters Kluwer Health in Indian Journal of Pathology and Microbiology
- Vol. 68 (3) , 592-595
Coexistence of BCR::ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series
BCR::ABL1 translocation and JAK2V617F mutations are canonical variants of myeloproliferative neoplasms (MPNs). Traditionally considered mutually exclusive, they may rarely coexist. We report the clinicopathological profile and treatment outcomes of four MPN patients with coexistence of these disease-defining genetic variants. Both mutations were detected simultaneously in three patients who did not harbor tell-tale signs of CML and were evaluated for both BCR::ABL1 and JAK2V617F based on clues from hemogram, peripheral-blood and bone-marrow examination. All were treated with imatinib and hydroxyurea and attained major molecular response after 2–7 months. In another patient, JAK2V617F was detected 15 years after the diagnosis of CML at the time of evaluation of loss of hematological and molecular response. She was treated with dasatinib but no hematologic or molecular response was attained after 6 months despite good compliance. In conclusion, BCR::ABL1 and JAK2V617F may rarely coexist in MPN with variable temporal evolution, clinicopathological profile, and treatment response.
- 5 July 2024
- Published by Wolters Kluwer Health in Indian Journal of Pathology and Microbiology
- Vol. 68 (3) , 592-595
Open AccessCoexistence of BCR::ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series
BCR::ABL1 translocation and JAK2V617F mutations are canonical variants of myeloproliferative neoplasms (MPNs). Traditionally considered mutually exclusive, they may rarely coexist. We report the clinicopathological profile and treatment outcomes of four MPN patients with coexistence of these disease-defining genetic variants. Both mutations were detected simultaneously in three patients who did not harbor tell-tale signs of CML and were evaluated for both BCR::ABL1 and JAK2V617F based on clues from hemogram, peripheral-blood and bone-marrow examination. All were treated with imatinib and hydroxyurea and attained major molecular response after 2–7 months. In another patient, JAK2V617F was detected 15 years after the diagnosis of CML at the time of evaluation of loss of hematological and molecular response. She was treated with dasatinib but no hematologic or molecular response was attained after 6 months despite good compliance. In conclusion, BCR::ABL1 and JAK2V617F may rarely coexist in MPN with variable temporal evolution, clinicopathological profile, and treatment response.
- 9 April 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (4) , 704-709
Clinicopathological and Immunophenotypic Characteristics of Series of ZNF384 Re-arranged Acute Leukemias
Rearrangement involving ZNF384 gene (ZNF384-r) is recently being described in acute leukemias. We present the clinic-pathological and immunophenotypic findings in a series of five cases of acute leukemia with ZNF384-r reported in our Institute between September 2020 to September 2023. Notably, while TCF3::ZNF384 fusion was the most frequently encountered abnormality, the fusion partner was not identified in two patients with ZNF384-r BCP-ALL. Immunophenotypically, patients presenting as B-cell precursor acute lymphoblastic leukemia (BCP-ALL) had a distinct profile characterized by weak or absent CD10 expression and the presence of myeloid markers such as CD13/CD33. Our findings underscore the importance of recognizing the distinct immunophenotypic features of ZNF384-r leukemias, particularly in cases presenting with atypical BCP-ALL or B/Myeloid mixed phenotype acute leukemia phenotypes. Moreover, these findings highlight the necessity for tailored diagnostic algorithms in clinical laboratories to facilitate the timely and accurate diagnosis of this clinically relevant leukemia subtype.
- 9 April 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (4) , 704-709
Clinicopathological and Immunophenotypic Characteristics of Series of ZNF384 Re-arranged Acute Leukemias
Rearrangement involving ZNF384 gene (ZNF384-r) is recently being described in acute leukemias. We present the clinic-pathological and immunophenotypic findings in a series of five cases of acute leukemia with ZNF384-r reported in our Institute between September 2020 to September 2023. Notably, while TCF3::ZNF384 fusion was the most frequently encountered abnormality, the fusion partner was not identified in two patients with ZNF384-r BCP-ALL. Immunophenotypically, patients presenting as B-cell precursor acute lymphoblastic leukemia (BCP-ALL) had a distinct profile characterized by weak or absent CD10 expression and the presence of myeloid markers such as CD13/CD33. Our findings underscore the importance of recognizing the distinct immunophenotypic features of ZNF384-r leukemias, particularly in cases presenting with atypical BCP-ALL or B/Myeloid mixed phenotype acute leukemia phenotypes. Moreover, these findings highlight the necessity for tailored diagnostic algorithms in clinical laboratories to facilitate the timely and accurate diagnosis of this clinically relevant leukemia subtype.